91 |
Photodynamic drug action on rat pancreatic acinar cellsCui, Zong Jie January 1989 (has links)
No description available.
|
92 |
Sterol biosynthesis in Aspergillus and its inhibition by azole antimycoticsParker, Stephen R. January 1991 (has links)
No description available.
|
93 |
Pharmacokinetic and biopharmaceutical studies of cyclosporine in the dog and of salicylate in humans.Abdallah, Hisham Youssef. January 1989 (has links)
Cyclosporine (CsA) is commercially available for oral administration as a solution in olive oil with alcohol and an emulsifier. This formulation suffers from the disadvantages of poor and highly variable absorption, objectionable taste and difficulty in measuring the prescribed dose by visually impaired patients. Several oral formulations were prepared and tested in vitro and in vivo in dogs. Based on these preliminary results the dosage form chosen for evaluation was a tablet formulation prepared by direct compression. These tablets were compared to the commercial oil solution placed into soft gelatin capsules. In order to determine absolute bioavailability and to avoid the concern of time-dependent clearance, an intravenous tracer dose of ³H-CsA was simultaneously administered with each oral test product on each of two occasions. Absolute bioavailability was 46.0 ± 11.1% and 45.4 ± 9.9% for the capsules and tablets, respectively. C(max), t(max) and MRT were not significantly different between the two products. No differences were observed in the pharmacokinetics of the intravenously administered CsA in the two experiments which were separated by 8-13 days. The elderly, usually defined as people over 65 years of age, constitute about 12% of the U.S. population. It has been estimated that one out of four elderly people is arthritic and is, therefore, a candidate for chronic salicylate therapy. The pharmacokinetics of salicylate following a single oral solution dose of 600 mg of sodium salicylate were investigated in 22 healthy, nonsmoking male subjects. The plasma concentration and urinary excretion of salicylic acid and its metabolite, salicyluric acid, as well as the urinary excretion of salicyl glucuronides were monitored. Urinary recovery essentially accounted for the administered dose and was not influenced by age, nor was the apparent oral clearance of salicylic acid. Assuming no presystemic elimination, it could be concluded that systemic availability is unaffected by age. An increase in the apparent volume of distribution, V(area), and a decrease in the maximum plasma salicylic acid concentration with age were observed. Renal clearance of salicyluric acid decreased significantly with age and was found to correlate significantly with creatinine clearance.
|
94 |
THE ROLE OF NEURAL TISSUE CONCENTRATION IN ACRYLAMIDE NEUROTOXICITY.Rylander, Leslie A. January 1984 (has links)
No description available.
|
95 |
THE ROLE OF COENZYME-A IN ACRYLAMIDE NEUROTOXICITY IN THE RAT.Miller, Mary Jo. January 1982 (has links)
No description available.
|
96 |
Design and synthesis of inhibitors of enzymes in the folate biosynthesis pathwayGuiney, Daniel January 2001 (has links)
No description available.
|
97 |
Investigation into the modification of the A-ring of analogues of 4-quinolonesO'Leary, Ruth January 1988 (has links)
No description available.
|
98 |
Danofloxacin pharmacodynamic and pharmacokinetic interrelationships in ruminant speciesShojaee Aliabadi, Fariborz January 1997 (has links)
No description available.
|
99 |
Characterization of human gene products homologous to fission yeast multi-drug resistance determinantsMontesanti, Annalisa January 2001 (has links)
No description available.
|
100 |
Characterisation of protein foams using a method based on conductivity measurement and measurement of physical properties of protein solutions relevant to foaming behaviourPhianmongkhol, Aphirak January 2000 (has links)
No description available.
|
Page generated in 0.0658 seconds